Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
News | November 27, 2024
Recently we proudly hosted our first Capital Markets Day, welcoming around 50 investors and key stakeholders.
The program featured insights from our executive management team and external speakers, followed by a Q&A session and a unique opportunity to explore our state-of-the-art facilities. This event marked an important step in strengthening our dialogue with the financial community and sharing our vision, strategy, and future opportunities.
To ensure everyone has the chance to see the event, the recording is available here: https://ir.financialhearings.com/devyser-cmd-2024
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Read More
Devyser announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant...
Read More
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More